QTRX completed its acquisition of Akoya Biosciences, resulting in massive revenue growth (+255%) but dramatically worsening losses and cash burn while depleting cash reserves by nearly half.
The acquisition fundamentally transformed the company's scale but raised serious questions about integration costs and cash runway sustainability. The disproportionate increase in losses relative to revenue gains, combined with rapidly declining cash position, suggests potential execution challenges or higher-than-expected integration expenses that investors should monitor closely.
While revenue surged 255% to $37.6M from the Akoya acquisition, the company's financial health deteriorated significantly with net losses expanding to -$107.2M and operating cash flow declining to -$77.2M. Cash reserves plummeted 47% to just $29.8M while total liabilities increased 61% to $123.0M, creating a concerning cash runway situation. The massive increase in inventory (+67%) and current liabilities (+78%) alongside declining current assets suggests integration challenges and working capital strain that could pressure liquidity in the near term.
Strong top-line growth of 255.3% — accelerating demand or successful expansion into new markets.
Net income declined 178.1% — review whether driven by operations, interest costs, or non-recurring items.
Operating income deteriorated sharply — investigate whether driven by one-time charges or structural cost issues.
Operating cash flow fell 119.6% — earnings quality concerns; investigate working capital changes and non-cash items.
Current liabilities surged 78% — significant near-term obligations; verify ability to meet short-term debt.
Inventory surged 67.1% — growing significantly faster than typical sales pace; potential demand softening or supply chain overcorrection.
Liabilities grew 60.8% — significant increase in debt or obligations, assess impact on financial flexibility.
Cash declined 47.4% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.
Current assets declined 41.6% — monitor working capital adequacy and short-term liquidity.
SG&A up 35.8% — significant increase in sales or administrative costs, monitor impact on operating leverage.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →